Cargando…

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)

OBJECTIVE: There is no standard care for advanced non–small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study aimed to assess the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yong, Wu, Yi-Long, Cao, Le-Jie, Chen, Jian-Hua, Ma, Zhi-Yong, Cui, Jiu-Wei, Wang, Jie, Liu, Hong-Bing, Ding, Jing-Yan, Hu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493697/
https://www.ncbi.nlm.nih.gov/pubmed/30950859
http://dx.doi.org/10.1097/COC.0000000000000538
_version_ 1783415202285355008
author Song, Yong
Wu, Yi-Long
Cao, Le-Jie
Chen, Jian-Hua
Ma, Zhi-Yong
Cui, Jiu-Wei
Wang, Jie
Liu, Hong-Bing
Ding, Jing-Yan
Hu, Min
author_facet Song, Yong
Wu, Yi-Long
Cao, Le-Jie
Chen, Jian-Hua
Ma, Zhi-Yong
Cui, Jiu-Wei
Wang, Jie
Liu, Hong-Bing
Ding, Jing-Yan
Hu, Min
author_sort Song, Yong
collection PubMed
description OBJECTIVE: There is no standard care for advanced non–small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study aimed to assess the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC patients with EGFR mutation. MATERIALS AND METHODS: It was a multicenter, open-label, single-arm, phase II study. Stage IIIB/IV NSCLC patients with EGFR exon 19del/L858R mutation, who had benefited from first-line gefitinib treatment followed by second-line chemotherapy, received gefitinib 250 mg/d. The primary objective was disease control rate (DCR) at week 8. RESULTS: Predefined DCR was achieved in 69.8% (95% confidence interval, 49.87-74.91) patients and objective response rate was reported in 4.7% (95% confidence interval, 0.78-13.06) patients. Median progression-free survival (PFS) was 4.4 months and overall survival (OS) was 10.3 months. Baseline T790M-negative patients achieved favorable DCR compared with T790M-positive patients (78.1% vs. 45.5%, P=0.0418), significantly longer median PFS (4.7 vs. 2.0 mo, P=0.0009) and median OS (15.2 vs. 7.7 mo, P=0.0132). We observed a negative correlation of PFS (r=−0.4396, P=0.0032), and OS (r=−0.3630, P=0.0167) with mutation abundance of exon 19del/L858R at baseline. CONCLUSIONS: Re-challenge with gefitinib is effective and could be a choice for third-line patients after the first-line EGFR-TKI treatment and second-line chemotherapy, especially for the T790M-negative patients.
format Online
Article
Text
id pubmed-6493697
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-64936972019-05-29 Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304) Song, Yong Wu, Yi-Long Cao, Le-Jie Chen, Jian-Hua Ma, Zhi-Yong Cui, Jiu-Wei Wang, Jie Liu, Hong-Bing Ding, Jing-Yan Hu, Min Am J Clin Oncol Original Articles: Thoracic OBJECTIVE: There is no standard care for advanced non–small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study aimed to assess the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC patients with EGFR mutation. MATERIALS AND METHODS: It was a multicenter, open-label, single-arm, phase II study. Stage IIIB/IV NSCLC patients with EGFR exon 19del/L858R mutation, who had benefited from first-line gefitinib treatment followed by second-line chemotherapy, received gefitinib 250 mg/d. The primary objective was disease control rate (DCR) at week 8. RESULTS: Predefined DCR was achieved in 69.8% (95% confidence interval, 49.87-74.91) patients and objective response rate was reported in 4.7% (95% confidence interval, 0.78-13.06) patients. Median progression-free survival (PFS) was 4.4 months and overall survival (OS) was 10.3 months. Baseline T790M-negative patients achieved favorable DCR compared with T790M-positive patients (78.1% vs. 45.5%, P=0.0418), significantly longer median PFS (4.7 vs. 2.0 mo, P=0.0009) and median OS (15.2 vs. 7.7 mo, P=0.0132). We observed a negative correlation of PFS (r=−0.4396, P=0.0032), and OS (r=−0.3630, P=0.0167) with mutation abundance of exon 19del/L858R at baseline. CONCLUSIONS: Re-challenge with gefitinib is effective and could be a choice for third-line patients after the first-line EGFR-TKI treatment and second-line chemotherapy, especially for the T790M-negative patients. Lippincott Williams & Wilkins 2019-05 2019-04-25 /pmc/articles/PMC6493697/ /pubmed/30950859 http://dx.doi.org/10.1097/COC.0000000000000538 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Articles: Thoracic
Song, Yong
Wu, Yi-Long
Cao, Le-Jie
Chen, Jian-Hua
Ma, Zhi-Yong
Cui, Jiu-Wei
Wang, Jie
Liu, Hong-Bing
Ding, Jing-Yan
Hu, Min
Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
title Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
title_full Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
title_fullStr Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
title_full_unstemmed Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
title_short Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
title_sort efficacy and safety of gefitinib as third-line treatment in nsclc patients with activating egfr mutations treated with first-line gefitinib followed by second-line chemotherapy: a single-arm, prospective, multicenter phase ii study (re-challenge, ctong1304)
topic Original Articles: Thoracic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493697/
https://www.ncbi.nlm.nih.gov/pubmed/30950859
http://dx.doi.org/10.1097/COC.0000000000000538
work_keys_str_mv AT songyong efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT wuyilong efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT caolejie efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT chenjianhua efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT mazhiyong efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT cuijiuwei efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT wangjie efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT liuhongbing efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT dingjingyan efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304
AT humin efficacyandsafetyofgefitinibasthirdlinetreatmentinnsclcpatientswithactivatingegfrmutationstreatedwithfirstlinegefitinibfollowedbysecondlinechemotherapyasinglearmprospectivemulticenterphaseiistudyrechallengectong1304